Agilent’s PD-L1 IHC 28-8 pharmDx gets added indications under EU IVDR1 for NSLC
Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
EurekAlert!7d
Ability of large language models to extract PD-L1 biomarker details from electronic health records
A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...
The American Journal of Managed Care7d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...